Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (abre una nueva ventana)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fuente‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexado en‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (abre una nueva ventana)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (abre una nueva ventana)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Fuente‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indexado en‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (abre una nueva ventana)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (abre una nueva ventana)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Fuente‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indexado en‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (abre una nueva ventana)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (abre una nueva ventana)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Fuente‎: Blood 2003;102(4):1529-30.

Indexado en‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (abre una nueva ventana)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (abre una nueva ventana)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fuente‎: Transfusion 2007;47(10):1830-6.

Indexado en‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (abre una nueva ventana)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (abre una nueva ventana)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fuente‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexado en‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (abre una nueva ventana)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (abre una nueva ventana)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fuente‎: Int J Hematol 2012;95(1):51-6.

Indexado en‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (abre una nueva ventana)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (abre una nueva ventana)

Perrine SP.

Fuente‎: Pediatr Ann 2008;37(5):339-46.

Indexado en‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (abre una nueva ventana)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (abre una nueva ventana)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fuente‎: Sci Rep. 2022;12(1):2752.

Indexado en‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (abre una nueva ventana)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (abre una nueva ventana)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fuente‎: Haematologica 2004;89(10):1172-8.

Indexado en‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (abre una nueva ventana)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (abre una nueva ventana)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fuente‎: Arch Iran Med 2009;12(3):295-7.

Indexado en‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (abre una nueva ventana)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (abre una nueva ventana)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Fuente‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indexado en‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (abre una nueva ventana)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (abre una nueva ventana)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Fuente‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indexado en‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (abre una nueva ventana)

Fetal globin gene inducers: novel agents and new potential. (abre una nueva ventana)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Fuente‎: Ann N Y Acad Sci 2010;1202:158-64.

Indexado en‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (abre una nueva ventana)